Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vicore Pharma (VCRE) will participate in the DNB Carnegie Nordic Healthcare Conference in Oslo, Norway, on November 24, 2026.
Chief Operating Officer Mikael Nygård will join a panel on idiopathic pulmonary fibrosis, a lung-scarring disease, from 1:45–2:05 PM CET. The company's participation also includes one-on-one meetings.
Key Terms
idiopathic pulmonary fibrosis medical
orphan drug designation regulatory
fast track designation regulatory
angiotensin ii type 2 receptor agonist medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
STOCKHOLM, SE / ACCESS Newswire / November 17, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the DNB Carnegie Nordic Healthcare Conference.
Location: Oslo, Norway
Format: Panel discussion and 1×1 meetings
Panel: Idiopathic Pulmonary Fibrosis | Three shots at reversing IPF - the Nordic fibrosis race
Date and time: Tuesday, November 24, 2026, 1:45-2:05 PM CET
Participant: Mikael Nygård, Chief Operating Officer
For further information, please contact:
Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
Attachments
Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference
SOURCE: Vicore Pharma Holding
View the original press release on ACCESS Newswire